Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2005
05/10/2005US6890512 Methods of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby
05/10/2005US6890339 Stent lining
05/10/2005US6889923 Powder processing
05/10/2005CA2407562C Tryptophan source from plants and uses therefor
05/10/2005CA2279743C Pharmaceutical composition of hedgehog proteins and use thereof
05/10/2005CA2251987C Microparticles
05/10/2005CA2232541C Fractionated vegetable oil
05/10/2005CA2183367C Ready-to-use indomethacin collyre
05/10/2005CA2159353C Microcapsules with walls made of cross-linked plant polyphenols, and compositions containing same
05/10/2005CA2153856C Duloxetine enteric pellets
05/10/2005CA2116192C Highly concentrated tcf pharmaceutical preparations
05/10/2005CA2025298C Novel process for the preparation of lipidic microparticulates
05/06/2005WO2005040365A1 Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
05/06/2005WO2005040353A2 Immunogenic compostion and method of developing a vaccine based on psoralen inactivated hiv
05/06/2005WO2005040352A2 Immunogenic composition and method of developing a vaccine based on factor h binding sites
05/06/2005WO2005040349A2 Immunogenic composition and method of developing a vaccine based on cyclophilin a binding site
05/06/2005WO2005040247A1 Polymeric composition for drug delivery
05/06/2005WO2005040228A2 Disintegratable films for diagnostic devices
05/06/2005WO2005040206A1 Glurp-msp3 fusion protein, immunogenic compositions and malarial vaccines containing it
05/06/2005WO2005040195A2 Formulation of exendins
05/06/2005WO2005040105A2 Novel surfactants and applications thereof
05/06/2005WO2005039750A1 Novel microparticles for ultrasound contrast imaging and drug delivery
05/06/2005WO2005039685A1 Transdermal drug delivery method and system
05/06/2005WO2005039668A2 Implantable drug delivery device for sustained release of therapeutic agent
05/06/2005WO2005039642A1 Dna delivery with gemini cationic surfactants
05/06/2005WO2005039623A1 Spray formulation for the treatment of viral infections
05/06/2005WO2005039620A1 Stable aqueous g-csf-containing compositions
05/06/2005WO2005039608A1 Remedy ointment for piles and their manufacturing method
05/06/2005WO2005039605A1 Pharmaceutical composition comprising oxoplatin, the salts and derivatives thereof
05/06/2005WO2005039602A1 Pharmacologically functional water and use thereof
05/06/2005WO2005039580A1 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
05/06/2005WO2005039577A1 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain
05/06/2005WO2005039576A1 Combinations of potassium channel openers and sodium channel inhibitors or active substances influencing sodium channels in order to treat painful conditions
05/06/2005WO2005039571A1 Therapeutic agent for keratoconjunctiva disorder
05/06/2005WO2005039561A1 Micronized bicyclol and the orally administered controlled release formulation
05/06/2005WO2005039558A1 Targeted delivery of therapeutically active compounds
05/06/2005WO2005039555A1 Extended release tablet formulations of venlafaxine
05/06/2005WO2005039553A1 Compositions for the treatment and prevention of cancer
05/06/2005WO2005039551A2 Solid pharmaceutical dosage form comprising an hiv protease inhibitor solid dispersion
05/06/2005WO2005039543A1 Self-supporting films for pharmaceutical and food use
05/06/2005WO2005039542A1 Drug-containing coated microparticle for orally disintegrating tablet
05/06/2005WO2005039541A1 Coenzyme q10 enclosing capsule
05/06/2005WO2005039540A1 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
05/06/2005WO2005039539A1 ORAL FORMULATION OF LIPID SOLUBLE THIAMINE, LIPOIC ACID, CREATINE DERIVATIVE, AND L-ARGININE α-KETOGLUTARATE
05/06/2005WO2005039538A1 Process for producing coated preparation having relieved unpleasantness
05/06/2005WO2005039537A1 Composition comprising biodegradable hydrating ceramics for controlled drug delivery
05/06/2005WO2005039536A1 Antibiotic compositions
05/06/2005WO2005039535A1 Preparation of lipid particles
05/06/2005WO2005039534A1 Lipophilic drug delivery vehicle and methods of use thereof
05/06/2005WO2005039533A1 Method of administering cationic liposomes comprising an active drug
05/06/2005WO2005039532A1 Microemulsions of retinoids, and pharmaceutical compositions containing them
05/06/2005WO2005039531A1 Transdermal pharmaceutical formulation for minimizing skin residues
05/06/2005WO2005039530A1 Methods and compositions for treating erectile dysfunction
05/06/2005WO2005039529A1 Microsphere of two anti-tubercular drugs and a biodegradable polymer administered by inhalation alone or combined with oral route, and process thereof
05/06/2005WO2005039528A2 Composition for the treatment of arthrosis/arthritis, especially for treating joints
05/06/2005WO2005039527A2 Extended release pharmaceutical dosage form
05/06/2005WO2005039526A1 Method, reagent and device for embolizing capillary vessel in tumor with supersonic tiny-bubble reagent
05/06/2005WO2005039525A1 Skin care and cleansing compositions containing oil seed product
05/06/2005WO2005039501A2 Immunogenic composition and method of developing a vaccine based on fusion protein
05/06/2005WO2005039499A2 Rapidly disintegrating film
05/06/2005WO2005039481A2 Oral drug delivery system
05/06/2005WO2005039474A1 Digestible and volume adjustable multi medication delivery device
05/06/2005WO2005039464A1 Transdermal high and low molecular weight compounds
05/06/2005WO2005039393A2 Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
05/06/2005WO2005039287A2 Formulation of a synergistic insecticidal composition as a cyclodextrin-complex
05/06/2005WO2005027895A3 Thyroid hormone analogs and methods of use in angiogenesis
05/06/2005WO2005018566A3 Topical delivery system containing colloidal crystalline arrays
05/06/2005WO2005011628A3 Oral delivery system comprising a biliquid foam
05/06/2005WO2005009436A8 Dispersible formulation of an anti-inflammatory agent
05/06/2005WO2005009368A3 Antibiotic product, use and formulation thereof
05/06/2005WO2005004849A3 Pharmaceutical formulation comprising levothyroxine sodium
05/06/2005WO2005003168A3 Methods for the production and cytotoxicity evaluation of kir2dl nk-receptor antibodies
05/06/2005WO2004110520A3 Improved system and method for facilitating hemostatis with an absorbable sponge
05/06/2005WO2004105702A3 Foamable pharmaceutical compositions and methods for treating a disorder
05/06/2005WO2004100994A3 Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances
05/06/2005WO2004096218A3 Pellet formulations of acid-labile antiulcer benzimidazole compounds
05/06/2005WO2004091539A3 Fluid mixing methods and apparatus
05/06/2005WO2004091537A3 Process for making gel films
05/06/2005WO2004091495A3 Compositions and methods related to production of erythropoietin
05/06/2005WO2004091487A3 Hemophilia treatment by inhalation of coagulation factors
05/06/2005WO2004080427A3 Method of preventing and treating infections that attack mucosa and assisting rehabilitation thereafter using topically applied ascorbic acid
05/06/2005WO2004080419A3 Humanized antibodies that recognize beta amyloid peptide
05/06/2005WO2004080383B1 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
05/06/2005WO2004064736A3 Treatment of benign prostatic hyperplasia using energolytic agents
05/06/2005WO2004019901A3 Sustained release pharmaceutical composition
05/06/2005CA2689639A1 Solid pharmaceutical dosage form
05/06/2005CA2546203A1 Extended release tablet formulations of venlafaxine
05/06/2005CA2546199A1 Extended release pharmaceutical dosage form
05/06/2005CA2544291A1 Transdermal drug delivery method and system
05/06/2005CA2543847A1 Insecticide formulation
05/06/2005CA2543779A1 Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
05/06/2005CA2543555A1 Therapeutic agent for keratoconjunctival disorder
05/06/2005CA2543454A1 Drug-containing coated microparticles for quick-disintegrating oral tablets
05/06/2005CA2542804A1 Preparation of lipid particles
05/06/2005CA2542708A1 Dna delivery with gemini cationic surfactants
05/06/2005CA2542434A1 Combination of flupirtine and tolperisone or eperisone for the treatment of painful conditions
05/06/2005CA2542238A1 Antibiotic compositions
05/06/2005CA2542217A1 Method of administering cationic liposomes comprising an active drug
05/06/2005CA2541990A1 Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and l-arginine .alpha.-ketoglutarate
05/06/2005CA2541511A1 Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein
1 ... 1823 1824 1825 1826 1827 1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 ... 2991